BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vectibix panitumumab regulatory update

Amgen requested re-examination of a negative opinion from EMA's CHMP for an MAA to expand the label of Vectibix panitumumab to include combination with chemotherapy to treat metastatic colorectal cancer in patients with wild-type ...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >